Active Substance: Sertraline (as HCl).
Overview
Welcome to Dwaey, specifically on SETRAL 50 page.
This medicine contains an important and useful components, as it consists of
Sertraline (as HCl)is available in the market in concentration
Sertraline Hydrochloride
Patient w/ family history of bipolar disorder, mania or hypomania; previous seizure disorder or condition predisposing to seizures (e.g. alcoholism, brain damage); angle-closure glaucoma or history of glaucoma; risk factors for uric acid nephropathy, QTc prolongation. Patient w/ concurrent systemic illness (e.g. conditions that affect metabolism or haemodynamic process). Avoid abrupt withdrawal. Renal and hepatic impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor BMI (longitudinal monitoring), height, wt, unusual behavioural changes, signs and symptoms of serotonin syndrome. Lactation Distributed into milk; use caution (AAP states effect on nursing infants is unknown but may be of concern)
Major Depressive illness, Panic disorder, Premenstrual dysphoric disorder, Post-traumatic stress disorder, Obsessive-compulsive disorder, Social anxiety disorder
Sertraline is contraindicated in patients with a known hypersensitivity to Sertraline or any of the excipients of drug. Concurrent use or w/in 14 days of discontinuation of MAOIs (e.g. linezolid or IV methylene blue). Concomitant use w/ pimozide.
>10% Diarrhea (13-24%),Nausea (13-30%),Headache (20-25%),Insomnia (12-28%),Ejaculation disorder (7-19%),Dizziness (6-17%),Dry mouth (6-16%),Fatigue (10-16%),Drowsiness (2-15%) 1-10% Agitation (1-6%),Anorexia (5-10%),Anxiety (4%),Constipation (5-8%),Paresthesia (2%),Impotence (5-10%),Sweating (< 1%),Malaise (7-9%),Vomiting (4%),Pain (3-6%) Frequency Not Defined Asthenia,Back pain,Chest pain,Hypoesthesia,Increased appetite,Myalgia,Palpitations,Rhinitis,Tinnitus,Weight gain,Yawning
3
Sertraline has a potent and selective inhibitory action on CNS neuronal reuptake of 5-HT resulting in increased 5-HT concentrations at the synaptic clefts, leading to sustained activity at the postsynaptic receptor sites and improvement of depression. Reduction of serotonin turnover (in brain) also contributes to its action. Its long half-life allows once daily admin.
May increase risk of delirium when used with antimuscarinics. Increased risk of extrapyramidal symptoms and neuroleptic malignant syndrome when used with aripiprazole. Serum levels may be reduced by carbamazepine. Concurrent use with dihydroergotamine or linezolid may lead to serotonin syndrome. May increase serum levels of lamotrigine and risk of toxicity. May increase serum levels of olanzapine, pimozide, risperidone, methadone, clozapine and amiodarone. Plasma levels may be increased by cimetidine and ritonavir. May increase the anticoagulant activity of warfarin and acenocoumarol. Potentially Fatal: Concomitant admin with MAOIs can result in serious serotonin syndrome.
Information not available